This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
The company had achieved the highest "A" rating in Climate Change
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
While Merck can appeal, Halozyme said it expects the order to hold
It's an acquisition that aims at forming one of the US's largest oncology trial networks
The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Subscribe To Our Newsletter & Stay Updated
